Research Gaps and Underfunded Questions in Cardiac Catheterization

Written by BlueRipple Health analyst team | Published December 14, 2025

Introduction

Medical research answers the questions that get asked and funded. In cardiac catheterization, commercial interests heavily influence which questions receive attention. Device manufacturers fund studies of new stents and imaging technologies. Questions without commercial sponsors often go unstudied.

This funding pattern creates blind spots. Important clinical questions may lack definitive answers not because they are unanswerable but because no one profits from answering them. Understanding these gaps helps patients recognize where evidence is robust versus where uncertainty persists.

This article examines research gaps in catheterization and the structural factors that perpetuate them.

What important questions about catheterization remain unanswered?

The optimal threshold for intervention remains debated. FFR values below 0.80 indicate hemodynamically significant stenosis, but this threshold emerged from limited data. Whether interventions at values between 0.75 and 0.85 provide benefit, and for which patients, remains incompletely understood.

Long-term outcomes beyond 5 years receive limited study. Most stent trials follow patients for 1-5 years. Yet patients live decades after intervention. How stented arteries behave over 10, 20, or 30 years—including very late thrombosis risk and the fate of polymer coatings—remains inadequately characterized.

The question of who benefits most from catheterization for stable disease lacks precise answer. Clinical trials show no average benefit for the intervention group, but averages obscure variation. Some patients likely benefit substantially while others do not. Identifying which patients fall into which category would enable more personalized decision-making.

Why is there limited research on optimal patient selection for catheterization?

Research on patient selection requires different study designs than device approval studies. Identifying which patients benefit requires randomizing intervention versus non-intervention—trials that device manufacturers have no incentive to conduct. Such studies might show that fewer patients need their products.

The ISCHEMIA trial represented a rare, large-scale investigation of patient selection for stable ischemic heart disease. It required federal funding from the National Heart, Lung, and Blood Institute precisely because no commercial entity would sponsor research potentially reducing intervention volume.

Studies that might reduce procedure utilization face structural headwinds. Academic medical centers and hospitals depend on catheterization revenue. Researchers affiliated with these institutions may face implicit pressure against studies that could reduce volumes. This creates subtle bias against research that might curtail intervention.

What studies comparing catheterization to intensive medical therapy are needed?

Existing trials compared intervention to usual medical therapy of their era. As medical therapy improves—with more potent statins, PCSK9 inhibitors, and emerging therapies—the relative benefit of intervention may shrink further. Updated comparisons against contemporary optimal medical therapy would inform current decisions.

Trials examining intensive lifestyle intervention as an alternative to catheterization would address questions that matter to lifestyle-focused patients. However, such trials are expensive, require long follow-up, and have no commercial sponsor. The patients most motivated to participate might not represent typical patients considering catheterization.

Studies examining de-escalation strategies—whether patients already stented could safely discontinue dual antiplatelet therapy earlier, or whether certain patients never needed intervention—would inform ongoing management but lack commercial support.

Why has research on reducing unnecessary catheterization been limited?

Research demonstrating that catheterization is unnecessary reduces procedure volume and therefore revenue for device manufacturers, hospitals, and interventional cardiologists. No commercial entity benefits from such findings. Public funding for such research competes with disease-focused research that has stronger advocacy.

Appropriate use criteria represent an effort to define necessary versus unnecessary catheterization, but applying these criteria prospectively requires investment that payors have been slow to make. Demonstrating that restricting catheterization to appropriate indications maintains outcomes while reducing costs would require substantial research investment.

Quality improvement initiatives have reduced inappropriate catheterization at some institutions, but publishing these results often reveals baseline inappropriate rates that institutions prefer not to publicize. This creates disincentive for transparency about overuse.

What are the barriers to conducting more sham-controlled catheterization trials?

The ORBITA trial demonstrated that sham-controlled trials of catheterization are feasible and provide information unavailable from open-label trials. The finding that stenting did not improve exercise time compared to sham procedure challenged assumptions about intervention benefit.

However, sham-controlled trials face ethical concerns. Subjecting patients to catheterization without intervention raises questions about risk without direct benefit. Informed consent for sham procedures is complex. Regulatory bodies in some countries are uncomfortable approving sham arms.

Practical barriers exist as well. Sham-controlled trials require maintaining blinding, which complicates standard care pathways. They require robust medical therapy in both arms, which demands more intensive management than usual care. These factors increase trial complexity and cost.

How have commercial interests shaped the catheterization research agenda?

Device manufacturers fund research that supports their products. Studies demonstrating stent superiority, new imaging modality utility, or physiological measurement value attract industry sponsorship. Studies questioning whether these technologies are necessary do not.

Key opinion leaders who design and interpret clinical trials often have industry financial relationships. These relationships may unconsciously bias study design and interpretation toward conclusions favorable to sponsors. Disclosure requirements have increased transparency but have not eliminated the underlying influence.

Publication bias compounds commercial bias. Positive trials demonstrating new technology benefit are more likely to be published and publicized than negative trials showing no benefit. Medical literature thus presents a systematically optimistic view of intervention benefit.

What questions about long-term outcomes after catheterization need study?

Very late stent thrombosis—occurring years after stent placement—has been recognized but incompletely characterized. Current drug-eluting stents appear safer than first-generation devices, but long-term follow-up data remain limited. Understanding risk factors for very late thrombosis would inform duration of antiplatelet therapy.

Lifetime management of stented patients deserves study. How should surveillance be conducted? When is repeat catheterization appropriate? How do stented arteries behave as patients age and comorbidities accumulate? These questions affect millions of patients but lack systematic study.

The fate of bioresorbable scaffolds years after absorption remains uncertain. While the scaffolds are designed to disappear, their long-term effects on vessel biology and clinical outcomes require extended follow-up that is only now becoming available.

Why is research on catheterization decision-making and patient preferences underfunded?

Shared decision-making research lacks commercial sponsor. Understanding how to help patients make informed catheterization decisions does not sell devices. Communication training for physicians does not generate revenue for device manufacturers.

Patient preferences research reveals heterogeneity that complicates one-size-fits-all guidelines. Some patients prefer aggressive intervention; others prefer conservative management. Respecting this variation means different patients with similar anatomy may receive different treatment—a concept that fits poorly with standardized device marketing.

Decision aid development requires investment in research, validation, and implementation without clear return on investment. Philanthropic and public funding remain the only sources for such work, and these sources are limited relative to commercial research budgets.

What studies on optimal catheterization timing and technique are needed?

The timing of catheterization after non-ST-elevation acute coronary syndrome remains debated. Guidelines recommend early invasive strategy within 24-72 hours, but optimal timing within this window is unclear. Research addressing specific timing may not interest device manufacturers who benefit from any intervention regardless of timing.

Technique optimization studies—comparing different approaches to lesion preparation, stent sizing, or adjunctive imaging—often compare new technologies to standard approaches rather than optimizing existing techniques. Manufacturers have no incentive to prove that existing equipment, optimally used, equals new equipment.

Radiation reduction techniques deserve more study. Cumulative radiation exposure affects both patients and catheterization laboratory staff. Research on minimizing exposure while maintaining procedural quality would benefit public health but lacks commercial interest.

How could research better address which patients benefit most from catheterization?

Subgroup analyses of existing trials provide some patient selection information but are limited by trial design and power. Prospective studies designed to identify benefit predictors would require different approaches than efficacy trials.

Machine learning applied to large datasets might identify patient characteristics predicting benefit from intervention. Such research requires access to comprehensive registries linking pre-procedure characteristics to long-term outcomes. Data sharing and standardization challenges limit such research.

Genetic predictors of response to intervention represent a largely unexplored area. Patients with certain genetic profiles might benefit more or less from catheterization. This pharmacogenomic approach to procedure selection could personalize decisions but requires substantial research investment.

Conclusion

Important questions about cardiac catheterization remain unanswered because answering them serves no commercial interest. Research funding structures favor studies of new technologies over studies questioning whether existing technologies are overused or optimally applied.

Patients should recognize that evidence gaps are not random. Where evidence is robust, commercial entities have had reason to generate it. Where evidence is thin, the questions may have been important but unfunded. This pattern creates systematic bias toward intervention in the evidence base.

Advocacy for publicly funded research, support for academic independence from commercial influence, and demand for transparency about conflicts of interest all help address these structural problems. Until then, patients must navigate a landscape where some questions have been well-studied while others equally important remain inadequately addressed.